Evidence map›Paper›PMID 39444031›Full record

Trial reportTrials2024

Web-based training and certification of clinical staff during the randomised clinical trial SafeBoosC-III.

Marie Isabel Skov Rasmussen, Mathias Lühr Hansen, Colin Peters, Gorm Greisen, SafeBoosC-III Trial Group

Registry-linked trialAbstract readMulticenter StudyPragmatic Clinical TrialRandomized Controlled Trial
In one paragraph

Trial report in Trials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03770741 (Safeguarding the Brain of Our Smallest Children - an Investigator-initiated, Pragmatic, Open Label, Multinational Randomized Phase IIIclinical Trial Evaluating Treatment Based on Near-infrared Spectroscopy Monitoring Versus Treatment as Usual in Premature Infants), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03770741 nacompletednot on this map

Safeguarding the Brain of Our Smallest Children - an Investigator-initiated, Pragmatic, Open Label, Multinational Randomized Phase IIIclinical Trial Evaluating Treatment Based on Near-infrared Spectroscopy Monitoring Versus Treatment as Usual in Premature Infants

TypeinterventionalSponsorGorm GreisenRan2019 to 2021Enrolled1,601ConditionsInfant, Extremely Premature, Brain Injuries, Death, Brain, DeathArmsModify cardio-respiratory support to avoid cerebral hypoxia, Treatment as usual
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marie Isabel Skov RasmussenDepartment of Neonatology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. marie.isabel.skov.rasmussen@regionh.dk.ORCID http://orcid.org/0000-0001-9277-9215
Mathias Lühr HansenDepartment of Neonatology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Colin PetersDepartment of Neonatology, Royal Hospital for Children, Glasgow, UK.
Gorm GreisenDepartment of Neonatology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
SafeBoosC-III Trial Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSafeBoosC-III is a pragmatic, multinational clinical trial evaluating cerebral oximetry-guided treatment for extremely preterm infants. In total, 1601 infants were randomised across 70 sites in Asia, Europe, and USA. To enhance data quality and patient care, a web-based training program was implemented for staff. We now report on the processes.

methodsAll training modules consisted of initial learning material followed by a case-based quiz, with elaborate responses to correct as well as to wrong answers. Modules covered trial introduction, cerebral oximetry monitoring, treatment guidelines, cerebral ultrasound, and Good Clinical Practice. The introduction module was accessible in eight languages on an online platform, while language versions varied for other modules, due to different needs. Certification was earned upon module completion, relevant to the staff category. The training was not mandatory, but for motivational purposes, principal investigators continuously received local certification rate reports.

resultsA total of 926 out of 2347 staff (39%) obtained certification. Amongst 295 staff who completed the evaluation, 83% rated the program as overall good and 94% found it relevant to clinical practice. Sites exhibited varying certification rates, with 10 at 0%, 43 between 0.1 and 79.9%, and 17 exceeding 80%. There was no correlation between the rate of certification in individual sites and how often the clinical management was changed due to cerebral hypoxia nor a correlation to site-specific estimates of the intervention effect.

conclusionDespite language barriers and a low budget, our web-based training and certification program proved feasible. Only a minority of sites reached 80% certification of staff and an impact on the trial could not be detected.

trial registrationThe SafeBoosC-III trial is registered at ClinicalTrials.gov NCT03770741. The first participant was randomised in June 2019 and recruitment was completed in December 2021.

Indexed as

CertificationOximetryCerebrovascular CirculationComputer-Assisted InstructionHealth PersonnelHumansInfant, Extremely PrematureInfant, NewbornInservice TrainingInternetInternet-Based Intervention

Identifiers

PMID39444031
PMCPMC11515472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.